VAUGHAN, Ontario—Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and AcuFocus, Inc., a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus. AcuFocus has delivered breakthrough small aperture intraocular technology to address the diverse unmet needs in eyecare, including the IC-8 Apthera intraocular lens (IOL), which was approved by the U.S. Food and Drug Administration in July 2022.

The IC-8 Apthera is the first and only small aperture non-toric extended depth of focus (EDOF) IOL for certain cataract patients who have as much as 1.5 diopters of corneal astigmatism and wish to address presbyopia at the same time. 

The IC-8 Apthera IOL features proprietary small aperture technology that enables both distance vision correction and near vision correction to mitigate the effects of presbyopia. Known as the IC-8 IOL in global markets, this IOL is available in select markets across Europe, as well as in Australia, New Zealand and Singapore.

Joseph C. Papa, CEO of Bausch + Lomb, said, “Cataracts are the largest contributor to global blindness in adults aged 50 years and older, with more than 15 million individuals, or approximately 45 percent of the more than 33 million cases of global blindness. We believe that the IC-8 Apthera EDOF IOL will bolster our surgical portfolio by enhancing our IOL offerings, which is a strategic area of focus for Bausch + Lomb. We will continue to focus on areas of unmet medical need that we believe will help drive long-term growth in our core segments, and importantly, help us achieve our mission of helping people see better to live better.”

"Bausch + Lomb is a legacy name in eyecare with a fully integrated portfolio of offerings in eye health,” said Al Waterhouse, president and CEO, AcuFocus. “With its extensive development footprint and renowned commercial expertise, we believe Bausch + Lomb is best positioned to educate physicians about the IC-8 Apthera lens, and ultimately, ensure more cataract patients have access to this new IOL.”

BofA Securities served as exclusive financial advisor to AcuFocus in this transaction. Norton Rose Fulbright US LLP served as legal advisor to Bausch + Lomb, and Latham & Watkins LLP served as legal advisor to AcuFocus.